AdvanSix Inc. (ASIX) · Nov 4, 2026 · Earnings
Miss — Adj. EPS $(0.24) vs approximately $(0.05) consensus
AdvanSix’s Q3 earnings beat revenue expectations, but adjusted EPS missed as weaker production and raw-material inflation crushed margins.
AdvanSix is a vertically integrated chemicals producer trying to defend margins against inflation and soft industrial demand while funding SUSTAIN and evaluating future growth projects. The Q2 outlook already warned that nylon demand was soft, production output would be optimized, and cash flow should improve in the second half.
The quarter was a profitability miss, not a demand collapse. Sales reached $430.8 million, above the published consensus of roughly $426 million, but adjusted EPS was $(0.24) versus consensus near $(0.05). Pricing did most of the work: sales rose 15% on 17% favorable pricing while volume fell 2%.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Sales (Financial Highlights) | $430.8M (+15%) | $374.5M | $426M |
| Adjusted diluted EPS (Financial Highlights) | $(0.24) | $0.08 | $(0.05) |
| Adjusted EBITDA (Financial Highlights) | $14.6M (-41%) | $24.7M | |
| Adjusted EBITDA margin (Financial Highlights) | 3.4% (-320 bps) | 6.6% | |
| Free cash flow (Free Cash Flow reconciliation) | $29.7M | $0.1M |
The core operating problem remains unresolved. Adjusted EBITDA fell $10.1 million year over year despite higher pricing, because reduced output created unfavorable fixed-cost absorption and raw-material inflation outpaced the benefit from commercial execution. Caprolactam sales were essentially flat in dollars, but the company specifically identified lower caprolactam volume as the main source of the volume decline.
Cash generation improved, but mostly through working capital and lower spending. Quarterly free cash flow rose to $29.7 million from effectively zero a year earlier, helped by inventory reductions, accounts-payable movements, and capital expenditures falling to $18.3 million. That is useful balance-sheet support, but it does not offset the weaker earnings quality: nine-month free cash flow remained negative at $(32.3) million, and debt financing was added during the year.
Capital spending is now being managed more tightly rather than accelerated. The company now expects approximately $90 million of 2026 capital expenditures versus $116 million in 2025, consistent with its prior risk-based spending plan rather than a new growth acceleration. The refinancing completed in August provides liquidity, but it was already disclosed before this release and therefore adds little new information.
Bottom line: AdvanSix beat on revenue and produced better quarterly cash flow, but the important operating signal was another sharp margin and earnings deterioration. The filing leaves the company’s recovery story intact but weaker than expected, with production efficiency and input-cost absorption still the central issues.
Q4 2026 earnings report
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!